Detecting anti-PF4 antibodies remains the golden diagnostic method for heparin-induced thrombocytopenia (HIT) diagnosis with high sensitivity and specificity. Various lab tests detect anti-PF4 antibodies, including immunoassays and functional assays. Even with positive detection of the anti-PF4 antibody, several factors are involved in the result. The concept of anti-PF4 disorders was recently brought to light during the COVID pandemic since the development of vaccine-induced thrombotic thrombocytopenia (VITT) with the adenovirus-vectored-DNA vaccine during the pandemic. Circumstances that detect anti-PF4 antibodies are classified as anti-PF4 disorders, including VITT, autoimmune HIT and spontaneous HIT. Some studies showed a higher percentage of anti-PF4 antibody detection among the population infected by COVID-19 without heparin exposure and some supported the theory that the anti-PF4 antibodies were related to the disease severity. In this review article, we provide a brief review of anti-PF4 disorders and summarize the current studies of anti-PF4 antibodies and COVID-19 infection.

Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. However, achieving a pathologic complete response (pCR) has proven to be inconsistent, and despite treatment, roughly half of patients experience locoregional recurrence or metastasis. Consequently, there has been a paradigm shift towards exploring the potential of immunotherapy in reshaping the landscape of LAEC management. Recent research has particularly focused on immune checkpoint inhibitors, investigating their application in both neoadjuvant and adjuvant settings. These inhibitors, designed to block specific proteins in immune cells, are meant to enhance the immune system's ability to target and combat cancer cells. Emerging evidence from these studies suggests the possibility of a mortality benefit, indicating that immunotherapy may contribute to improved overall survival rates for individuals grappling with esophageal cancer. This manuscript aims to meticulously review the existing literature surrounding neoadjuvant and adjuvant immunotherapy in the context of LAEC management. The intention is to thoroughly examine the methodologies and findings of relevant studies, providing a comprehensive synthesis of the current understanding of the impact of immunotherapy on esophageal cancer.

While high-dose therapy and autologous stem cell transplant (ASCT) remain integral to the primary treatment of newly diagnosed transplant-elble multiple myeloma (MM) patients, the challenge of disease progression persists. The primary objective of this meta-analysis is to evaluate the efficacy and safety of tandem ASCT compared to single ASCT. We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing tandem ASCT with single ASCT in patients with newly diagnosed MM. We searched PubMed, EMBASE, Cochrane Library, and Clinical Trials databases for studies published up to January 2024. The primary outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR), complete response rate (CRR), and treatment-related mortality (TRM). We used a random-effects model to calculate pooled hazard ratios (HRs) and relative risks (RRs) with 95% confidence intervals (CIs). Study quality was assessed using the Cochrane risk of bias tool and Newcastle–Ottawa Scale. Twelve studies involving 5057 patients met the inclusion criteria. Tandem ASCT was associated with a significantly higher CRR compared to single ASCT (HR 1.33, 95% CI 1.03–1.71, I2 = 15%), but no significant differences were observed in PFS (HR 0.75, 95% CI 0.42–1.34, I2 = 14%), OS (HR 0.60, 95% CI 0.33–1.10, I2 = 27%), or the ORR (RR 0.80, 95% CI 0.59–1.08, I2 = 33%). However, tandem ASCT was associated with a significantly higher risk of TRM (RR 1.78, 95% CI 1.00–3.18, I2 = 0%). Tandem ASCT improves the CRR but does not provide significant benefits in terms of PFS, OS, or ORR compared to single ASCT in patients with newly diagnosed MM. Moreover, tandem ASCT is associated with a higher risk of TRM. The decision to pursue tandem ASCT should be made on an individual basis, carefully weighing the potential benefits and risks in light of each patient’s unique clinical situation. Future research should focus on identifying patient subgroups most likely to benefit from tandem ASCT and exploring strategies to optimize the efficacy and safety of this approach in the context of novel agent-based therapies.

Background: Medical image analysis plays a crucial role in the screening, monitoring, diagnosis, and prognosis of diseases. Hepatocellular Carcinoma (HCC) often remain asymptomatic in their early stages. Timely identification and intervention are crucial to prevent the progression to decompensated liver diseases and advanced-stage HCC, minimizing morbidity and mortality. Methodology: This study examined twenty relevant research articles that met the inclusion criteria. Utilizing the PRISMA criteria, a systematic search was conducted on PubMed/MEDLINE and Google Scholar for studies on HCC screening employing Artificial Intelligence (AI) and Machine Learning (ML). The search focused on the keywords "artificial intelligence" and "hepatocellular carcinoma," with inclusion criteria specifying studies in the English language published in and after 2020. Exclusions were made for histology, animal research, and investigations conducted before 2020. Titles and abstracts were thoroughly reviewed, and any discrepancies were discussed. Results: The comprehensive review reveals the transformative impact of AI and ML on HCC screening, diagnosis, and therapy. ML models demonstrated effectiveness in early HCC diagnosis, distinguishing hepatic lesions, predicting treatment responses, and assessing recurrence risks across various techniques. Integration of mass spectrometry-based technologies, advanced imaging, and real-world data significantly improved diagnostic accuracy and clinical decision support. AI models exhibited diagnostic expertise with potential applications in therapy suggestions, personalized surveillance, and prognostic evaluations. However, further validation and seamless integration into clinical practice are essential for realizing their full potential. Conclusion: This systematic study underscores the progress made in the application of AI and ML in HCC screening, diagnosis, and treatment. Numerous studies highlight the capability of AI and ML systems to enhance hepatocellular carcinoma diagnosis, predict outcomes, and optimize therapy. The enduring and versatile nature of these technologies points towards a revolutionary future in personalized and efficient HCC management.

We report the case of a 42-year-old female diagnosed with acute promyelocytic leukemia (APL), who developed differentiation syndrome (DS) on day 14 during induction therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with sudden-onset dyspnea, abdominal pain, tachycardia, and fever. Her laboratory findings were remarkable for acute kidney injury (AKI), worsening leukocytosis, thrombocytopenia, and lactic acidosis. She was also found to have flash pulmonary edema and a pericardial effusion. Despite immediate dexamethasone and methylprednisolone administration along with cessation of induction therapy, she continued to worsen and suffered a non-shockable cardiac arrest. Return of spontaneous circulation (ROSC) was achieved, but she was in profound shock requiring multiple vasopressors. The patient suffered repeat cardiac arrest later that day and passed away within 24 hours. DS is a potentially life-threatening complication in APL treatment, occurring in about 25% of APL patients and posing significant treatment challenges.

This systematic review explores the role of artificial intelligence (AI) and machine learning (ML) technologies in the diagnosis and treatment of thyroid cancers (TC), focusing on enhancing precision, risk assessment, and tailored care. By analyzing ten studies, the review highlights how AI and ML technologies, such as deep learning (DL) and computer-aided diagnostics (CAD), improve the accuracy of ultrasound imaging, risk stratification, and the detection of high-risk nodules. Despite advancements, challenges persist in transitioning to personalized care, including uneven prognostication and diagnostic uncertainty. The review evaluates the effectiveness of AI and ML compared to conventional methods, their ability to address diverse tumor characteristics, and their strengths and limitations in prognosis prediction. Findings suggest AI's potential in improving precision and risk assessment, but limitations such as inconsistent approaches and biases highlight the need for larger datasets and standardized procedures. Moreover, the review underscores the importance of interpretability and transparency in AI models and calls for further research to validate findings in clinical settings. Despite limitations and challenges, AI's transformative potential in TC management is evident, underscoring the need for ongoing investigation and integration into clinical practice.

Objective: The objective of this study is to thoroughly investigate the use of artificial intelligence (AI) and machine learning (ML) techniques for diagnosing and predicting prognosis in gastric cancer, utilizing the latest available data. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)guidelines, a systematic review investigated AI and ML applications in gastric cancer diagnosis and prognostic prediction. PubMed and Google Scholar were searched from February 2019 to January 2024 using specific syntax. Eligible trials were selected based on inclusion criteria including recent publication, focus on AI and ML in gastric cancer, and reporting diagnostic or prognostic outcomes. Data were extracted and quality assessed independently, with discrepancies resolved through discussion. Due to design heterogeneity, detailed analysis was omitted, and descriptive summaries of included articles were provided. Results: This review included a total of 8 articles. AI and ML techniques, including convolutional neural networks (CNN) and deep learning models, have played pivotal roles in accurately diagnosing chronic atrophic gastritis, predicting postoperative gastric cancer prognosis, and identifying peritoneal metastasis in gastric cancer patients. These technologies offer potential advantages such as streamlining diagnostic procedures, guiding treatment decisions, and enhancing patient outcomes in gastric cancer management. Conclusion: In the near future, AI applications may have a significant role in the diagnosis and prognosis prediction of gastric cancer.

The objective of this study was to examine the characteristics and utilization patterns of palliative care among the kidney cancer patients using a large-scale representative population-based sample. We retrospectively analyzed National Inpatient Sample hospitalization data from January 2020 to December 2020 to explore disparities in delivering palliative care to deceased kidney cancer patients and assess its impact on healthcare usage, focusing on hospital costs and length of stay (LoS). We used ICD-10 CM codes (International Classification of Diseases-classifying diagnoses and reasons for visits in all healthcare settings) to categorize the study population. We conducted univariable and multivariable linear and logistic regression analyses to calculate coefficients and odds ratios, considering relevant variables and addressing potential confounding factors. We studied 1437 deceased kidney cancer patients, with 53.9% receiving palliative care. Those receiving palliative care had lower total costs ($99,804 vs. $1,34,731) and a shorter LoS (7.19 days vs. 7.66 days), compared to those who didn’t. No significant difference was discovered in LoS. Private insurance, higher income, and female patients were more likely to receive palliative care. Race, hospital teaching status, and hospital size showed no significant differences. This study revealed insights into palliative care use among deceased kidney cancer patients, with cost-saving benefits evident. Disparities showed that individuals with private insurance and higher income more likely accessed palliative care, and females received it more often than males. Physicians and policymakers must consider these findings for equitable resource allocation and improved access.

Context Hemophagocytic histiocytosis (HLH) is a rare and life-threatening disorder characterized by the hyperactivation of cytotoxic T lymphocytes and natural killer cells, leading to a cytokine storm and macrophage activation. COVID-19 induces a dysregulated immune response and infrequently gives rise to HLH. Objective Limited data exist on the occurrence of HLH in COVID-19, prompting our investigation into this specific population. Methods This retrospective study used the National Inpatient Sample (NIS) database, covering January 2020 to December 2020. COVID-19 hospitalizations were detected through use of ICD-10 codes. We divided these hospitalizations into 2 specific groups: those with and without HLH. Our primary focus was on in-hospital mortality, length of hospitalization, and total charges incurred during the hospital stay, while our secondary objectives involved investigating complications and associations associated with HLH in COVID-19. The statistical analysis involved the application of multivariate models adjusted for potential confounding factors. Results Of the 331,808 COVID-19 hospitalizations, 149 cases involved HLH. The HLH group, characterized by younger age, exhibited significantly higher mortality (38.25% vs 13.40%; adjusted odds ratio [aOR]=4.79; 95% confidence interval [CI], 2.98-7.72; P<0.01). Additionally, the HLH group experienced prolonged hospital stays (16.5 vs 8 days; coefficient=7.91 days; 95% CI, 5.07-10.74; P<0.01) and accrued greater total charges ($310,483 vs $91,736; coefficient=$213,682; $67,518-$359,845; P<0.01). The HLH group exhibited elevated risks and adverse outcomes, including higher incidences of sepsis (aOR=3.65; 2.22-5.98; P<0.01), vasopressor support (aOR=5.49; 3.17-9.50; P<0.01), intubation/mechanical ventilation (aOR=5.32; 3.42-8.26; P<0.01), acute kidney injury (aOR=3.13; 2.08-4.73; P<0.01), encephalopathy (aOR=3.49; 2.32-5.25; P<0.01), and acute liver injury (aOR=3.43; 1.60-7.35; P<0.01). Additionally, the HLH group had a significantly higher risk of anemia (aOR=1.76; 1.17-2.66; P<0.01), thrombocytopenia (aOR=2.26; 1.33-3.85; P<0.01), pancytopenia (aOR=3.58; 1.65-7.77; P<0.01), GI bleeding (aOR=3.24; 1.85-5.67; P<0.01), DIC (aOR=8.34; 3.33-20.88; P<0.01), and the need for RBC transfusion (aOR=4.18; 2.36-7.40; P<0.01), platelet transfusion (aOR=7.53; 2.64-21.53; P<0.01), and fresh frozen plasma transfusion (aOR=2.96; 1.38-6.36; P<0.01). Conclusion Our study reveals a substantial impact of HLH on COVID-19 outcomes, highlighting increased mortality, resource utilization, and associated complications. Understanding these associations is crucial for the timely recognition and management of HLH in patients with COVID-19, informing clinical strategies and resource allocation.

Objective:Acute promyelocytic leukemia (APL) is associated with an elevated risk of developing disseminated intravascular coagulation (DIC). The purpose of this study was to assess the outcomes of hospitalizations related to DIC in APL and their impact on healthcare.Materials and Methods:This study entailed a cross-sectional and retrospective analysis of the US National Inpatient Sample database. We identified adults with APL and categorized them into groups of patients with and without DIC. Our focus areas included in-hospital mortality, length of stay, charges, and complications associated with DIC. Unadjusted odds ratios/coefficients were computed in univariate analysis, followed by adjusted odds ratios (aOR)/coefficients from multivariate analysis that accounted for confounding factors.Results:Our analysis revealed that APL patients with DIC had a substantially higher aOR for mortality (aOR: 6.68, 95% confidence interval [CI]: 4.76-9.37, p<0.001) and a prolonged length of stay (coefficient: 10.28 days, 95% CI: 8.48-12.09, p<0.001) accompanied by notably elevated total hospital charges (coefficient: $215,512 [95% CI: 177,368-253,656], p<0.001), thereby emphasizing the reality of extended medical care and economic burden. The presence of DIC was associated with increased odds of sepsis, vasopressor support, pneumonia, acute respiratory failure, intubation/mechanical ventilation, and acute kidney injury, reflecting heightened vulnerability to these complications. Patients with DIC demonstrated significantly higher odds ratios for major bleeding, intracranial hemorrhage, gastrointestinal bleeding, red blood cell transfusion, platelet transfusion, fresh frozen plasma transfusion, and cryoprecipitate transfusion, highlighting the pronounced hematological risks posed by DIC.Conclusion:This study has revealed the significant associations between DIC in APL and various outcomes, underscoring the clinical and economic implications of these conditions. The hematological risks further increase patients’ vulnerability to bleeding events and the need for transfusions.

Context Social media has dramatically altered the dissemination of medical information, particularly in resource-limited areas. Alarmingly, 32.5% of cancer-related articles on social media contain misinformation, with 77% of this misinformation being potentially harmful and leading to negative consequences. To address this critical issue, MedNews Week (MNW) was established as a digital educational platform with the aim to combat misinformation by offering free live presentations from global oncology experts. This study aims to evaluate the reach and impact of MNW in addressing medical misinformation and enhancing healthcare education worldwide. Design Between January 2022 and May 2024, MNW hosted 15 renowned oncology experts as keynote speakers. Data on impressions and viewership were systematically collected from MNW's social media channels, including Twitter, LinkedIn, and YouTube. Data were analyzed to assess MNW's global viewership, as well as engagement levels, stratified by gender, age group, and occupational background. Results The analysis showed that MNW recorded 4731 interactions and 109,128 impressions, reaching 1.9 million Twitter accounts during this time period. Viewership showed consistent growth: 20,527 (6 months), 50,707 (1 year), 290,532 (1.5 years), 302,145 (2.5 years). Moreover, MNW's audience spanned more than 100 countries, including 23 low-tomiddle Human Development Index (HDI) nations. The majority of followers were male, and 73.44% of followers were from nonhealthcare backgrounds. Conclusions MNW has effectively bridged significant knowledge gaps and successfully combated misinformation by featuring international oncology leaders. Furthermore, this initiative has underscored inclusivity by actively engaging traditionally underserved communities, ultimately yielding a positive impact on oncology education and awareness on a global scale. Thus, this virtual platform demonstrates promising potential for global collaboration, subsequently enhancing cancer care and education worldwide.

In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. Recent advancements in our understanding of the intricate relationship between inflammation and oncogenesis, particularly involving the IL-1β/PD-1/PD-L1 pathway, have shed light on their application in lung cancer development and clinical outcomes of patients. Targeting these pathways in cancers like NSCLC holds immense potential to revolutionize cancer treatment, particularly for patients lacking targetable genetic mutations. However, despite these promising prospects, there remain certain aspects of this pathway that require further investigation, particularly regarding treatment resistance. Therefore, the objective of this review is to delve into the role of IL-1β in NSCLC, its participation in inflammatory pathways, and its intricate crosstalk with the PD-1/PD-L1 pathway. Additionally, we aim to explore the potential of IL-1β as a therapeutic target for NSCLC treatment.

Objective: The objective of this study was to examine the characteristics and utilization patterns of palliative care among lymphoma cancer patients using a large-scale representative population-based sample. Methods: Retrospective analysis was conducted on hospitalization data from the National Inpatient Sample (NIS) spanning January 2016 to December 2019. The study aimed to investigate the characteristics and disparities associated with the provision of palliative care to deceased lymphoma patients and evaluate its impact on healthcare utilization, specifically discounted hospital charges and length of stay (LOS). Multivariate linear and logistic regression analyses were performed, stratifying the data based on age, race, Charlson comorbidity index, insurance status, median household income, and hospital characteristics. The study population was classified and identified using ICD-10 codes. Results: We identified 10,323 deceased lymphoma patients from hospitalization records, among whom 52.9% (n=5,464) received palliative care during their hospital stay. Multivariate linear regression analysis demonstrated that the group receiving palliative care had significantly lower total charges, with a mean decrease of $24,269 (95% CI: $37,263 to $11,277, p < 0.001) compared to the group not receiving palliative care. However, there was no statistically significant difference in the adjusted length of stay between patients who received palliative care and those who did not (coefficient = -0.07 days, 95% CI = -0.69 to 0.54, p = 0.806). Multivariate logistic regression analysis indicated that patients with Black and Hispanic race had lower odds of receiving palliative care, while those admitted to larger and urban teaching hospitals had higher odds of receiving palliative care. Additionally, patients with Medicare had the lowest probability of receiving palliative care compared to other insurance groups. Conclusion: This study provides valuable insights into the utilization patterns and characteristics associated with palliative care among deceased lymphoma patients. The findings demonstrate that receiving palliative care is associated with significantly lower total charges, indicating its potential cost-saving benefits in healthcare utilization. However, no significant difference was observed in the adjusted length of stay between patients who received palliative care and those who did not. Furthermore, the study highlights disparities in access to palliative care, with Black and Hispanic patients having lower odds of receiving such care. Hospital characteristics, such as size and urban teaching status, were found to influence the likelihood of palliative care utilization. Additionally, patients with Medicare insurance had the lowest probability of receiving palliative care compared to other insurance groups. These findings underscore the need to address disparities in access to palliative care and ensure equitable provision for all lymphoma patients, irrespective of race or insurance status. Integrating palliative care into the treatment approach for lymphoma patients has the potential to optimize healthcare utilization and improve patient outcomes. Policymakers should consider these findings to enhance resource allocation and promote equitable access to palliative care services. Further research and implementation efforts are warranted to improve access and enhance the delivery of palliative care for lymphoma patients.

Background The impact of the Hospital Frailty Risk Score on outcomes in hospitalized bladder cancer patients is not studied. This study aims to investigate the association between frailty and bladder cancer outcomes. Methods Retrospective analysis used National Inpatient Sample data (January 2020 to December 2020) for patients with bladder cancer diagnoses (ICD10-CM codes C67.0-C67.9, D09.0). Hospital frailty score was calculated using ICD-10 index and comorbidities distribution of frailty score suggested in a study published by Gilbert et al.1 Multivariate analysis assessed frailty correlation, stratifying by sex, race, age, Charlson index, median annual income, hospital bed size, teaching status, and census division. Results Among 8,247 bladder cancer hospitalizations, 81.9% had intermediate to high frailty scores (IHFS) and 18.1% had low frailty scores (LFS). IHFS group had higher unadjusted in-hospital mortality (6.87% vs. 2.48%). IHFS patients had increased adjusted mortality odds (aOR=2.56, 95% CI [1.80–3.62], p=0.000). Adjusted mortality rate had no significant difference between males and females (aOR=0.17, 95% CI [-0.11 - 0.46], p=0.229). Black race patients had higher adjusted mortality odds than Caucasian race patients (aOR=1.69, 95% CI [1.17–2.42], p=0.005). IHFS group also had longer lengths of stay (aOR=2.27 days, 95% CI [2.02 - 2.53], p=0.000) and higher adjusted costs (aOR=$10,410.39, 95% CI [6,403.38 - 14,417.40], p=0.000) compared to the LFS group (table 1). Conclusions High hospital frailty risk scores in bladder cancer patients are associated with increased mortality rates, prolonged hospital stays, and higher adjusted costs. Assessing frailty aids in predicting outcomes and allows physicians to stratify patients based on risk levels for better management. Reference Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, Arora S, Street A, Parker S, Roberts HC, Bardsley M. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. The Lancet. 2018 May 5;391(10132):1775–82.

In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. In this review, we discuss the role of IL-1β in NSCLC, its involvement in inflammatory pathways, and explore its potential role in the treatment of NSCLC.

165 Background: Patients with recurrent or metastatic neuroendocrine tumors (NETs) have limited treatment options and a poor prognoses. Programmed death–ligand 1 (PD-L1) has been associated with the pathogenesis, progression, and prognosis of NETs. This article analyzes the efficacy and safety profile of PDL1 inhibitor Pembrolizumab in advanced NETs. Our objective is to identify all the clinical trials in which Pembrolizumab has been assessed in treating NETs and to evaluate the efficacy and safety profile in this patient population with high power. Methods: Systemic searches of PubMed, the Cochrane Library, and ClinicalTrials.gov were conducted with prespecified terms. The outcomes studied in our analysis were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and serious adverse events (AEs). We calculated the pooled ORR for these studies using weighted pooled ORR = Σ (ORR_i * weight_i). We calculated the standard error using the formula SE = √(Σ (wi x (1 - ORRi) x ORRi) / Σ (wi x ni)) and the 95% confidence interval using the formula CI = ORR ± (1.96 x SE). This statistical method was also used to calculate our study's pooled DCR, PFS, OS, and serious AEs. However, it is essential to note that the pooled data is only as reliable as the individual data estimates from each study and may be subject to bias or confounding factors. Results: Five clinical trials met the inclusion criteria, including patients with gastrointestinal, pancreatic, lung, and lower genital tract NETs. Outcome data were available for all five studies, comprising 177 patients with NETs who received Pembrolizumab as part of the treatment regimen (Table). The pooled ORR and DCR were 5.27% (95% CI 2.23-8.31) and 5.4% (95% CI 3-7.8), respectively. The pooled weighted PFS was 4.4 months, and pooled weighted OS was 23.3 months. These findings suggest that Pembrolizumab has a promising ORR, DCR, PFS, and OS. Safety was a secondary endpoint, and the pooled serious AEs were noted in 20.9% of patients. Conclusions: Pembrolizumab demonstrated statistically significant efficacy and safety profile in a subset of patients with NETs and was overall well-tolerated. In recent years, the combination strategy of tyrosine kinase inhibitors (TKI) with PDL-1 checkpoint inhibitors has shown promising clinical benefits in patients with various solid tumors. Further studies are needed to analyze the efficacy and safety of TKI with PD-L1 inhibitors in NETs. [Table: see text]

Abstract Apocrine carcinoma of the breast is a rare subtype of breast carcinoma, which only presents as 4% among patients with breast cancer. The percentage varies based on the diagnostic criteria used by each institution to classify apocrine carcinoma. Several confusing terms used in previous studies, including apocrine ductal carcinoma in situ (ADCIS), apocrine morphology in lobular carcinoma in situ (Apocrine LCIS), apocrine-like invasive carcinoma, pure apocrine carcinoma, molecular apocrine tumors (MATs), and triple-negative apocrine carcinoma of the breast (TNAC). The treatment, prognosis, and molecular profiles are also diverse. Pure apocrine carcinoma has stricter criteria for diagnosis, requiring more than 90% of cells showing apocrine morphology and classic IHC characteristics of ER-negative, PR-negative, and AR-positive in at least 10% of tumor cell nuclei. Research related to prognosis is diverse due to the difficulty of unifying the diagnostic criteria. Current evidence of treatment is geared toward the use of neoadjuvant chemotherapy and anti-androgen therapy when AR is present, accompanied by other treatments if biomarkers are present, such as HER2, PI3K, or CDK4/6. This article focuses on clearly summarizing different subtypes and management of apocrine carcinoma of the breast.

Background: Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), classically characterized by the translocation of t(11;14). MCL is typically CD10 negative, often attributed to its pre-germinal nature arising from naïve B cells. Increasing cases of CD10+ MCL suggest the possibility of germinal center-derived pathology. Moreover, a unique and rarer BCL6+/CD10+ immunophenotype has been reported in the literature and warrants investigation into its clinicopathologic significance. This meta-analysis was conducted to further investigate the relationship between MCL immunophenotypes and their clinical outcomes. Methods: A meta-analysis was conducted to investigate the relationship between MCL immunophenotypes and clinical outcomes. Endpoints collected included clinical features, overall survival (OS), morphology, immunophenotypes , Ki67%, and cytologic variants. OS data was pooled from multiple studies and assessed using the R programming package survival. A log-rank test was performed to compare OS. The mean differences in OS between BCL6+ and BCL6- MCL for individual studies were calculated and combined to minimize the batch effects. If individual Ki67 indexes were not available, the standard deviation (SD) of the mean difference was calculated based on normal distribution and the sample size of the particular study. The summary statistics across all studies was calculated by averaging all mean differences and pooling individual SDs. The correlations between CD10 & BCL6, BCL6 & blastoid morphology, and BCL6 & SOX11 were tested using Fisher's exact test. Statistical significance was determined by setting the alpha (α) level at 0.05. Results: The meta-analysis included 537 patients (425 males and 112 females). The median age of diagnosis in CD10+ and CD10- MCL was 69 and 61.5 years old, respectively. There were 70 CD10+, 467 CD10-, and 22 BCL6+/CD10+ patients. BCL6 positivity had an odds ratio of 5.11 (95% CI [2.49, 10.46]; p=0.00002386) for CD10 positivity compared to CD10 negativity. The subgroup analysis showed a higher frequency of blastoid/pleomorphic/small morphology variants in BCL6+/CD10+ MCL. Correlation analysis between BCL6 positivity and blastoid/pleomorphic/small morphology did not demonstrate significant correlation (p=0.2423). However, positive correlation was seen between BCL6 and SOX11 (p=0.013). BCL6+ MCL was associated with an inferior median OS compared to BCL6- MCL (BCL6+: 14 months vs. BCL6-: 43 months; p=0.01). Furthermore, BCL6+/CD10+ co-expression was associated with an inferior median OS compared to BCL6-/CD10+ MCL (BCL6+/CD10+: 20 months vs. BCL6-/CD10+: 55 months; p<0.01). Conclusion: Based on the analysis, it was found that BCL6 expression positivity negatively impacts overall survival (OS) in MCL, regardless of CD10 expression. The higher Ki67% observed in BCL6 expression positivity compared to BCL6 negativity suggests the prognostic value of the BCL6 immunophenotype in MCL. Additionally, BCL6 expression was found to be correlated with CD10 and SOX11 expression, indicating the clinical significance of these variables when combined with BCL6 positivity. It is suggested that prognostic scoring systems adjusted for BCL6 could provide further insights into the prognostic categorization, management, classification, and future tailored treatment of MCL variants.

Background: Insufficient data exists on COVID-19 risks and hospitalization outcomes in patients with immune thrombocytopenia (ITP). Our analysis aims to assess risks and outcomes associated with COVID-19 in ITP patients. Method: In this retrospective study, we obtained data from the National Inpatient Sample (NIS) database for the year 2020. Hospitalizations for ITP were identified using ICD-10 codes, further classified into those with and without COVID-19 infection (Table 1). To account for potential confounding factors, we considered variables such as age, sex, race, zip code-based income quartile, hospital region, hospital teaching status, hospital division, hospital bed size, and insurance status. Additionally, the Charlson index and relevant comorbid conditions such as smoking, alcohol use, illicit drug use, hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), atrial fibrillation (AF), liver disease, and chronic use of anticoagulants were included. Firstly, univariable logistic regression analysis calculated unadjusted odds ratios (ORs). Then, to adjust for potential confounders, a multivariable logistic regression analysis was performed to calculate adjusted odds ratios (aORs) (Table 2). The multivariable logistic regression model only included variables associated with the outcome of interest in univariable regression analysis at P < 0.1. Proportions were compared using the Fisher exact test, and continuous variables were compared using the Student t-test. All P-values were two-sided, with a significance threshold of .05. Results: Data from 10,831 hospitalizations for ITP in 2020 were gathered. Among those, 563 hospitalizations were of patients with COVID-19. Unadjusted data revealed minimal differences in the mean age between both groups, but there was a statistical difference between COVID-positive and COVID-negative males (48.2% vs. 42.9%) and females (51.8% vs. 57.0%). White race had the highest number of patients in both groups with a statistical difference of 62.5% vs. 68.5%, p=0.000 compared to other races. Moreover, COVID-positive patients with ITP had a significantly higher rate of comorbidities like hypertension (67.8% vs. 60.2%, p=0.000) and diabetes mellitus (38.5% vs. 28.9%, p=0.000). On the other hand, there was no statistical difference between groups with associated comorbidities like smoking, alcohol, illicit drugs, COPD, CHF, CAD, atrial fibrillation, liver disease, and chronic anticoagulation use. ITP patients with COVID-19 showed a significantly longer median length of stay (10.7 days vs. 6.3 days; p=0.000) and higher overall cost-of-hospitalization ($136,915 vs. $98,657; p=0.000). After adjusting for potential confounders using multivariate logistic regression, we found that ITP patients with COVID-19 had notably higher odds of mortality (adjusted odds ratio (aOR) = 5.42, 95% CI: 4.18 to 7.03, p=0.000), longer hospital stays (Coefficient: 4.31 days, 95% CI: 3.31 to 5.30, p=0.000), and increased total hospital charges (Coefficient: $37,243, 95% CI: $20,137 to $54,350, p=0.000). However, there were no statistically significant differences in the administration of PRBC transfusions, platelet transfusions, or immunoglobulin transfusions between the two groups. Additionally, no notable distinctions in the odds ratio of experiencing intracranial bleeding, gastrointestinal (GI) bleeding, myocardial infarction (MI), or acute cerebrovascular accident (CVA) were observed between ITP patients with and without COVID-19. Conclusion: In conclusion, this study highlights the higher risks and poorer hospitalization outcomes associated with COVID-19 in patients with immune thrombocytopenic purpura. The results of our study highlight the significance of taking COVID-19 infection into account when managing and evaluating outcomes in ITP patients, as it seems to be linked to more severe disease manifestations and higher utilization of healthcare resources. Further research and prospective studies are necessary to gain a deeper understanding and address the implications of COVID-19 in this particular patient population.